Related Experiment Video
Updated: Apr 19, 2026
Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer
Published on: July 28, 2010
Loss of ARHI expression in colon cancer and its clinical significance
Wei Wang1, Lili Chen2, Qun Tang3
1Departments of General Surgery, the First Affiliated Hospital, Henan University of Science and Technology, Luoyang, Henan 471000, China ; These authors contributed equally to this work.
Aim Of The Study:
The Ras-related tumour suppressor gene aplasia Ras homolog member I (ARHI) is downregulated in many types of cancer, including ovarian cancer and hepatocellular carcinoma. In the present study, we explore the expression level and role of ARHI in colon cancer. Moreover, the mechanisms that down-regulate expression of ARHI in colon cancer will be further investigated.
Material And Methods:
ARHI expression levels were evaluated with immunohistochemistry, reverse transcriptase-PCR, and western blot. Loss of heterozygosity (LOH), single strand conformation polymorphism (SSCP), and methylation-specific PCR (MSP) were used to study the mechanisms of ARHI down-regulation.
Results:
Low expression of ARHI was observed in 61.7% (37/60) of colon cancer specimens. Compared with the paired noncancerous tissues, ARHI expression was significantly decreased in colon cancer tissues. Furthermore, low ARHI expression was significantly associated with worse differentiation degree and Dukes' stage (P < 0.05). Methylation-specific PCR assay revealed that the methylation rates of ARHI were 53.3% (16/30) and 46.7% (14/30) in ARHI CpG I and CpG II, respectively. Therefore, methylation of promoter may be involving in down regulation of ARHI expression.
Conclusions:
These data highlight an important role for ARHI in colon cancer, which could be a therapeutic strategy against this malignancy.
Insights
Aplasia Ras homolog member I (ARHI) is downregulated in colon cancer, linked to poorer outcomes. Promoter methylation is a key mechanism driving this reduced ARHI expression, suggesting therapeutic potential.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Background:
- Aplasia Ras homolog member I (ARHI) is a tumor suppressor gene implicated in various cancers.
- ARHI downregulation is observed in ovarian cancer and hepatocellular carcinoma.
- The role and expression of ARHI in colon cancer require further elucidation.
Purpose of the Study:
- To investigate the expression level of ARHI in colon cancer.
- To explore the functional role of ARHI in colon cancer development.
- To identify the molecular mechanisms responsible for ARHI downregulation in colon cancer.
Main Methods:
- Immunohistochemistry, reverse transcriptase-PCR, and western blot were used to assess ARHI expression.
- Loss of heterozygosity (LOH), single strand conformation polymorphism (SSCP), and methylation-specific PCR (MSP) were employed to investigate ARHI downregulation mechanisms.
- Colon cancer and paired non-cancerous tissues were analyzed.
Main Results:
- ARHI expression was significantly decreased in 61.7% of colon cancer specimens compared to non-cancerous tissues.
- Low ARHI expression correlated with poorer differentiation and advanced Dukes' stage.
- Methylation-specific PCR indicated promoter methylation in 53.3% (CpG I) and 46.7% (CpG II) of cases, suggesting a role in ARHI downregulation.
Conclusions:
- ARHI plays a significant role in colon cancer pathogenesis.
- Reduced ARHI expression, potentially due to promoter methylation, is associated with adverse prognostic factors.
- ARHI represents a potential therapeutic target for colon cancer treatment.
Related Concept Videos
01:12Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
01:12Loss of Tumor Suppressor Gene Functions
01:20Inflammatory Bowel Disease IV: Clinical Manifestations
01:30Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...